Kyocera (TYO:6971) will transfer its medical business, including artificial joints and dental implants, to Kyocera Medical Corp., a newly established wholly-owned subsidiary, effective October 1, according to its Wednesday bourse filing.

The spin-off, approved by Kyocera's Board on May 28, aims to streamline compliance with stringent global medical regulations and accelerate growth in the specialized medical device sector.

Kyocera Medical will inherit 32.6 billion yen in assets, as of March 2025, and operate independently, with Kyocera retaining full ownership post-split.

The transaction is structured as a simplified absorption-type split, requiring no shareholder approval, and will not impact Kyocera's capital or core operations.